Low-dose of olanzapine has ameliorating effects on cancer-related anorexia.
appetite
cachexia
chemotherapy
end-of-life care
nausea
tranquilizer
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
10
4
2019
pubmed:
10
4
2019
medline:
10
4
2019
Statut:
epublish
Résumé
Olanzapine (OLZ) has become well-known for its antiemetic effects on chemotherapy-induced nausea and vomiting. However, it remains unclear whether OLZ also has efficacy for treating cancer-related anorexia. This study, therefore, retrospectively examined whether or not OLZ administration affects the food intake in anorexic cancer patients who exhibit neither nausea nor vomiting. Eighty patients prescribed OLZ were extracted from 951 inpatients who consulted with our palliative care team at Chiba University Hospital from April 2008 to March 2016. Their food intake described on a nursing record was compared before and after OLZ administration. The observation period was 3 days before and after the start of OLZ treatment, because most inpatients whose food intake increased were discharged in 3 days. In those 80 patients, the average dose of OLZ for 3 days was 2.28±0.87 (mean±SD) mg/day. First, the food intake in 80 patients was significantly higher after than before starting OLZ, and the relative change in food intake was 149% on average ( We have herein reported OLZ's ameliorating efficacy in cancer-related anorexia at the low dose of 1.5 mg/day. Although our study has many limitations, low-dose OLZ can be a promising treatment for cancer-related anorexia.
Sections du résumé
BACKGROUND
BACKGROUND
Olanzapine (OLZ) has become well-known for its antiemetic effects on chemotherapy-induced nausea and vomiting. However, it remains unclear whether OLZ also has efficacy for treating cancer-related anorexia. This study, therefore, retrospectively examined whether or not OLZ administration affects the food intake in anorexic cancer patients who exhibit neither nausea nor vomiting.
METHODS
METHODS
Eighty patients prescribed OLZ were extracted from 951 inpatients who consulted with our palliative care team at Chiba University Hospital from April 2008 to March 2016. Their food intake described on a nursing record was compared before and after OLZ administration. The observation period was 3 days before and after the start of OLZ treatment, because most inpatients whose food intake increased were discharged in 3 days.
RESULTS
RESULTS
In those 80 patients, the average dose of OLZ for 3 days was 2.28±0.87 (mean±SD) mg/day. First, the food intake in 80 patients was significantly higher after than before starting OLZ, and the relative change in food intake was 149% on average (
CONCLUSION
CONCLUSIONS
We have herein reported OLZ's ameliorating efficacy in cancer-related anorexia at the low dose of 1.5 mg/day. Although our study has many limitations, low-dose OLZ can be a promising treatment for cancer-related anorexia.
Identifiants
pubmed: 30962712
doi: 10.2147/CMAR.S191330
pii: cmar-11-2233
pmc: PMC6433113
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2233-2239Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
J Pain Symptom Manage. 2002 Jun;23(6):526-32
pubmed: 12067777
Support Care Cancer. 2005 Jul;13(7):529-34
pubmed: 15700131
Support Care Cancer. 2007 Nov;15(11):1285
pubmed: 17375339
Lancet Oncol. 2009 Feb;10(2):115-24
pubmed: 19135415
Support Care Cancer. 2010 Aug;18(8):951-6
pubmed: 19756773
J Child Adolesc Psychopharmacol. 2010 Apr;20(2):127-33
pubmed: 20415608
J Support Oncol. 2011 Sep-Oct;9(5):188-95
pubmed: 22024310
J Pain Symptom Manage. 2012 Oct;44(4):604-7
pubmed: 22771132
Case Rep Gastroenterol. 2014 Jan 10;8(1):13-7
pubmed: 24574944
Support Care Cancer. 2015 Sep;23(9):2649-54
pubmed: 25680763
Support Care Cancer. 2016 Feb;24(2):675-682
pubmed: 26130365
J Palliat Med. 2016 Jan;19(1):87-90
pubmed: 26398872
Support Care Cancer. 2016 Feb;24(2):1001-1008
pubmed: 26530228
Support Care Cancer. 2016 Jun;24(6):2393-5
pubmed: 26838020
Asia Pac J Clin Oncol. 2016 Sep;12(3):254-8
pubmed: 27030364
Pharm Pract (Granada). 2017 Jan-Mar;15(1):877
pubmed: 28503222
Jpn J Clin Oncol. 2017 Sep 1;47(9):840-843
pubmed: 28633504
Int J Clin Oncol. 2018 Apr;23(2):382-388
pubmed: 29039073